Drug Profile
BR 02001
Alternative Names: hCTLA4Ig - Boryung PharmaceuticalLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Recombinant fusion proteins
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis